Several studies have demonstrated that patients with T2D frequently do not reach glycemic target and their treatment intensification is often delayed, both in terms of initiating insulin and later intensifying insulin regimens–this is known as clinical inertia [7–10]. The gene discussed is INS; the disease is type 2 diabetes mellitus.